Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
127
resultados
Última actualización
21/05/2025 [07:39:00]
Resumen de: US2025152659A1
A method for preventing or treating Parkinson's disease including administering a patient in need thereof a pharmaceutical composition including a polypeptide, the peptide having an amino acid sequence I or II: I: FPGSDRF (SEQ ID NO: 1)-Z; II: X-FPGSDRF (SEQ ID NO: 1)-Z; S represents phosphorylated serine; X and Z independently represents an amino acid or an amino acid sequence; X is selected from F, (R)9 (SEQ ID NO: 2), (R)9-F (SEQ ID NO: 3), 6-aminohexanoic acid, 6-aminohexanoic acid-F, 6-aminohexanoic acid-(R)9 (SEQ ID NO: 2), 6-aminohexanoic acid-(R)9-F (SEQ ID NO: 3); and Z is selected from (G)n-RGD or A-(G)n-RGD (SEQ ID NO: 4), where n is an integer greater than or equal to 0, in the range of 0-10.
Resumen de: US2025152542A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: WO2025101004A1
The present invention relates to a 6-aryl imidazo(2,1-b)thi/oxazole-2-carboxilic acid derivative. The compound according to the present invention acts as a JNK3 inhibitor capable of acting specifically on JNK3. The compound according to the present invention has a relatively high inhibitory activity against JNK3 compared to inhibitory activities against JNK1 and JNK2, and thus can be used as a therapeutic agent for Alzheimer's disease with low risk of side effects.
Resumen de: US2025152539A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: WO2025100469A1
According to the present invention, it is found that a snake venom metaloproteinase SVMP (snake venom metalloproteinase) from a snake belonging to the family Viperidae, the family Elapidae or the like decomposes Aβ and cuts the Aβ at an α-position to suppress the formation of Aβ fibrils. When a protein containing a metaloproteinase domain of SVMP is administered or a gene for the protein is introduced and is expressed in the brain, the formation of Aβ fibrils can be suppressed and consequently Alzheimer's disease can be treated.
Resumen de: US2025152747A1
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a GCase polypeptide. Also provided are methods to treat Gaucher Disease or GBA-PD. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions, and kits for expressing an GCase polypeptide in an individual in need thereof.
Resumen de: US2025152541A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: US2025152540A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: WO2025098365A1
Disclosed are a levodopa nasal spray, a preparation method therefor, and use thereof. The levodopa nasal spray comprises levodopa or a pharmaceutically acceptable salt thereof, an absorption enhancer, a suspending agent, an antioxidant, a wetting agent, and an antimicrobial agent. The levodopa nasal spray enhances the stability of levodopa, increases olfactory region deposition of the drug, improves nasal-to-brain delivery efficiency, can effectively treat Parkinson's disease while reducing the occurrence of symptom fluctuations, and has suitable viscosity.
Resumen de: US2025152590A1
The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeuties to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXRα heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXRα function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXRα activating agents.
Resumen de: US2025152543A1
The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and/or mobility and/or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.
Resumen de: EP4553069A1
Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represented by formula I, wherein the definition of each group is as described in the description. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and strokes.
Resumen de: EP4552634A1
The present disclosure relates to a pharmaceutical composition useful for the prevention or treatment of diabetes, preservation of beta-cell function, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, which includes a sustained-release microsphere containing semaglutide or a pharmaceutically acceptable salt thereof, a bioavailability enhancer and a biodegradable polymer, so that the pharmaceutical composition do not have a high initial burst of drug, contain a high content of drug relative to the particle size and have a high bioavailability, and thus, can minimize pain and inflammatory response of patient that may occur when administered to the human body.
Resumen de: MX2025000057A
The present invention relates to the treatment of a ALS patient with oral fausdil at a dose of 180-240 mg/day, wherein the patient is treated beginning at least 24 months following disease onset. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Resumen de: WO2024011094A1
The present invention relates to the treatment of an ALS patient having disease onset of at least 24 months prior to initiation of treatment with fausdil. Fasudil is administered at a dose of 60-240 mg/day according to specific treatment regimens. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Resumen de: US2025146000A1
The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
Resumen de: US2025144159A1
A composition comprising a mixture of DHA and/or EPA in the form of glyceride or ethylester derived from at least one microorganism, such as a microalga, and at least one plant-derived phospholipid, in which the content of DHA and/or EPA in triglyceride form is between 10% and 90% by weight relative to the total weight of the composition, and the content of at least one plant-derived phospholipid, such as phosphatidylcholine, is between 10% and 90% by weight relative to the weight of composition. The method for manufacturing same and to the use thereof, in particular in the treatment of pathologies involving a deficiency of DHA and/or EPA, such as age-related macular degeneration or Alzheimer's disease.
Resumen de: US2025144135A1
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Resumen de: US2025145695A1
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to humanized TDP-43 specific binding molecules, in particular to humanized anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: WO2025097123A1
Aspects of the invention are drawn to methods for identifying or treating Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) in a subject. Further aspects of the invention are drawn to methods for screening the presence of an Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) signature.
Resumen de: WO2025097160A1
The present disclosure provides methods of enhancing levodopa therapeutic efficacy for the treatment of Parkinson's disease. The present methods can include administration of compounds having a triphenylphosphonium moiety. Advantageously, the present method can mitigate microbial metabolism of levodopa to dopamine in the gut, improve bioavailability of levodopa in brain, and increase dopamine levels in the brain.
Resumen de: WO2025095553A1
A pharmaceutical composition for preventing or treating dementia diseases, containing, as an active ingredient, an isoquinoline derivative compound or a pharmaceutically acceptable salt thereof, of the present invention, does not induce cytotoxicity and can alleviate learning and memory abnormalities in an animal model of Alzheimer's dementia, and thus is expected to be effectively used in the development of therapeutic agents for dementia diseases.
Resumen de: AU2023367200A1
The present disclosure provides methods for achieving optimal levels of bevemipretide (also known as "(R)-2-amino-N-((S)- 1 -(((S)-5-amino- 1 -(3 -benzyl- 1,2,4-oxadiazol-5- yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5- guanidinopentanamide" or "SBT-272"), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof, in brain tissue of subjects suspected of having, suffering from, or at risk for a neurodegenerative disease, such as, but not limited to amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), PD with dementia, dementia with Lewy bodies, Multiple System Atrophy, Huntington's disease, HTT proteinopathy, Frontotemporal Lobar Degeneration (FTLD), a tauopathy, and other disease where TDP-43, Tau protein, and α-synuclein are associated with the disease pathology.
Resumen de: US2025145722A1
Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
Nº publicación: WO2025093735A2 08/05/2025
Solicitante:
DRUG TARGET IP B V [NL]
DRUG TARGET IP B.V
Resumen de: WO2025093735A2
The present invention relates to an agent for use in decreasing the level of intracellular phosphorylated tau in neurons, which agent can bind ELAVL4 with a binding affinity of at least - 8.0 kcal/mol. The agent comprises a structural element selected from the group consisting of a steroid backbone, a sugar moiety by glycosidic linkage, an O-linked glucuronide, and a lactone group and is suitably selected from the group of porphyrins, macrolactams, macrolides, vitamin D glucuronides, steroid glucuronides, withanolides, cardenolide glycosides, anthracyclines, ergoloid mesylates, ergotamines and derivates thereof, biphenyls, and piperazines. The administration of said agent leads to a decrease in protein levels of phosphorylated tau in normal neurons treated with the agent as compared to non-treated normal neurons and to a decrease in the Aβ42/Aβ40 ratio in fAD neurons treated with the agent as compared to non-treated fAD neurons. The agent is administered for the treatment of a tauopathy, which may be involved in Alzheimer's disease, frontotemporal dementia, Parkinson's disease or progressive supranuclear palsy and multiple sclerosis.
BOPI
Sede Electrónica
